Established in 2006 as the SRI Center for Advanced Drug Research (SRI CADRE), SRI Shenandoah Valley (SRI SV) is housed in a recently completed 40,000 square foot research facility. This life sciences-focused research center advances the productivity of the pharmaceutical industry, as well as government agencies and foundations, including helping the nation develop life-saving treatments for major health challenges and opportunities, such as biomarkers, cancer, infectious diseases (H1N1 flue, HIV), neglected and rare diseases such as dengue fever, and new ways to neutralize biothreats. The Center's researchers take the research process from conceptualization to product delivery.
SRI SV is part of Silicon Vally-based SRI International, one of the world's leading independent research and technology development organizations. Founded as Stanford Research Institute in 1946, SRI has been meeting the strategic needs of clients and partners for 67 years. The nonprofit research institute performs sponsored research and development for government agencies, commercial businesses, and private foundations. In addition to conducting grant and contract R&D, SRI licenses its technologies, forms strategic partnerships, and creates spin-off companies. Innovations from SRI International have created new industries, billion of dollars of marketplace value, and lasting benefits to society -- touching our lives every day. Today, SRI has 2,500 employees located at more than 20 sites around the world. SRI SV is SRI's second location in Virginia; the Arlington site was one of the first offices to be established outside of SRI headquarters in Menlo Park, California.
An example of SRI SV's work is an NIH-funded platform for early diagnosis of fungal pneumonia, a curable yet terminal disease in 90% of patients because it goes undiagnosed or isn't identified early enough for treatment. Commercialization will have global reach.
Biomarkers are strategically important and are considered a keystone in the future of personalized medicine and healthcare delivery. These identifiers can be developed as potential diagnostics and disease indicators, and staff are applying and improving innovative approaches to identifying and characterizing biomarkers. Biomarkers are having an impact on everything SRI SV does, including taking biomarker research to pharmaceutical and biotechnology companies more extensively than in the past. Commercialization of this work is anticipated in the next several years.
Moving forward, SRI SV plans to engage increasingly in technology commercialization, partnering with large pharmaceutical and technology companies for research and development activities. RedCoat Solutions, located in Harrisonburg, Virginia, is SRI SV's first spin-off, and could be a "game-changer" for detection and, ultimately, control of bedbugs. Other examples of SRI SV's commitment to research and commercialization include multiple patent applications and more than 70 peer-reviewed research publications.
Strategic partnerships are also an integral part of the Center's success; an example is SRI SV's partnership with the University of Virginia (U.Va.) and Virginia Tech in the Virginia Innovation Partnership (VIP), which received an i6 Challenge award from the Economic Development Administration (EDA). SRI SV also maintains a collaborative relationship with James Madison University (JMU), partnering extensively through student internship programs, new technology programs, and other important initiatives, such as a global health research course at JMU.